TriSalus Life Sciences (NASDAQ:TLSI – Get Free Report) and Innovative Eyewear (NASDAQ:LUCY – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, institutional ownership, risk, earnings, analyst recommendations, dividends and profitability.
Earnings and Valuation
This table compares TriSalus Life Sciences and Innovative Eyewear”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| TriSalus Life Sciences | $45.15 million | 5.80 | -$39.23 million | ($1.30) | -3.27 |
| Innovative Eyewear | $2.66 million | 2.99 | -$7.59 million | ($1.29) | -0.71 |
Analyst Ratings
This is a breakdown of recent ratings for TriSalus Life Sciences and Innovative Eyewear, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| TriSalus Life Sciences | 1 | 1 | 3 | 0 | 2.40 |
| Innovative Eyewear | 1 | 1 | 0 | 0 | 1.50 |
TriSalus Life Sciences currently has a consensus price target of $10.20, indicating a potential upside of 140.00%. Given TriSalus Life Sciences’ stronger consensus rating and higher probable upside, analysts plainly believe TriSalus Life Sciences is more favorable than Innovative Eyewear.
Profitability
This table compares TriSalus Life Sciences and Innovative Eyewear’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| TriSalus Life Sciences | -62.59% | N/A | -64.47% |
| Innovative Eyewear | -225.26% | -88.90% | -80.34% |
Insider and Institutional Ownership
2.6% of TriSalus Life Sciences shares are held by institutional investors. Comparatively, 1.0% of Innovative Eyewear shares are held by institutional investors. 16.3% of TriSalus Life Sciences shares are held by company insiders. Comparatively, 1.7% of Innovative Eyewear shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Volatility & Risk
TriSalus Life Sciences has a beta of 0.47, indicating that its share price is 53% less volatile than the S&P 500. Comparatively, Innovative Eyewear has a beta of 2.74, indicating that its share price is 174% more volatile than the S&P 500.
Summary
TriSalus Life Sciences beats Innovative Eyewear on 10 of the 14 factors compared between the two stocks.
About TriSalus Life Sciences
TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado.
About Innovative Eyewear
Innovative Eyewear, Inc. develops and sells smart eyeglasses and sunglasses. The company's flagship product is Lucyd Lyte glasses that enable the wearer to listen to music, take and make calls, and use voice assistants to perform various smartphone tasks hands-free. It also offers Vyrb, a social media application that enables the user to receive and send posts through Lucyd Lyte smart glasses with voice. In addition, the company launches an application, Lucyd app for iOS/Android users. It sells its products through various e-commerce, and retail store and distribution channels. Innovative Eyewear, Inc. has a license agreement with Lucyd Ltd. The company was incorporated in 2019 and is headquartered in North Miami, Florida. Innovative Eyewear, Inc. is a subsidiary of Lucyd Ltd.
Receive News & Ratings for TriSalus Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TriSalus Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
